Identifier : journaloflaborat01cent ( find matches ) Title : The Journal of laboratory and clinical medicine Year : 1915 ( 1910s ) Authors : Central Society for

Central Society for Clinical Research (U.S.) (Wikimedia Commons) / No restrictions

Cure & Advancements/July 7, 2026/2 min read

Breakthrough T1D Extends SAB-142 Research: What the Expanded Study Means

A major funding organization is backing continued research into SAB-142 beyond its first 100 days of treatment. Here's what we know about this next phase of investigation.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Breakthrough T1D has committed support for SAB-142 research to continue past the initial 100-day treatment period
Extended study timelines help researchers understand how treatments perform over longer periods
SAB-142 remains in active investigation; results from expanded studies are still being gathered

Research Moves Into Extended Phase

Breakthrough T1D, a major organization supporting Type 1 diabetes research, has backed the continuation of SAB-142 studies beyond the first 100 days of treatment. This decision to extend the research timeline signals ongoing confidence in gathering more detailed data about how the therapy performs over time.

Why Longer Studies Matter

Clinical research rarely stops at short timeframes. Extending studies beyond initial treatment periods allows researchers to observe how therapies affect patients over months and longer, revealing patterns and outcomes that early data may not show. This approach helps build a more complete picture of safety and effectiveness.

What's Next

SAB-142 continues to be investigated as a potential therapeutic approach for Type 1 diabetes. As with all experimental treatments, results from expanded research will need to be carefully evaluated and published before any conclusions can be drawn about its role in diabetes treatment.

Evidence label

Origin: Stock Titan (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.